Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Many investors that go back to the 90’s used to post on here.
They have all left now. As I have posted before, the only way APDN has ever generated positive cash flow is by issuing more shares every year. Then when the number of shares goes beyond 20 million and dilution sinks the stock below a buck, Hayward gets a delisting notice. He then reverse splits the shares to regain compliance.
To my knowledge, the company has never shown a profit.
I am not surprised to see legal proceedings commenced. It should have happened over 10 years ago.
Many investors that go back to the 90’s used to post on here.
They have all left now. As I have posted before, the only way APDN has ever generated positive cash flow is by issuing more shares every year. Then when the number of shares goes beyond 20 million and dilution sinks the stock below a buck, Hayward gets a delisting notice. He then reverse splits the shares to regain compliance.
To my knowledge, the company has never shown a profit.
I am not surprised to see legal proceedings commenced. It should have happened over 10 years ago.
I think this SmartWater revelation is not good news. APDN spent years and lots of capital testing their marker in England.
This stock is tanking. AGAIN
My research shows that each kit is high volume, professional and clinically licensed use only. An order of 10,000 kits must mean they are going to testing facilities nationwide. These must be very expensive per kit:
https://www.fda.gov/media/138059/download
The home test kits(non professional) range from $150-$185.
I believe these professional kits for high volume lab testing are much more.
Has anyone heard how much they are??
The majority will be shipped this month. I would assume the price per kit might be over 200$??
Right, I figured that PR on Friday was to soften this blow.
Hayward knows how to reel in fish. It’s the only way he has ever made a dime.
As far as I know, this is the first Time Hayward has ever released preliminary data.
My bet is he hooked a fish at those two investor conferences. Recent stock pps might have undermines the deal precipitating and immediate need to do some cpr.
And, if you really look at what Takis is saying, it’s a joke. Human trials of 100 individuals? To be completed next April? Talk about too late!!
And these NY high schools? I laughed out loud when I read that one! Especially the part about the fact they have no funding.
Yes, Takis never mentions APDN for months now.
This stock is being dumped ahead of earnings and dilution.
Historically, Hayward has only made money by issuing stock. This has been happening on a regular basis for over twenty years with regular dilutions.
Also, Hayward never tells shareholders when the so called joint ventures collapse into nothing. Cotton, fertilizers, COVID-19, on and on. The list of losers is staggering.
Nutrition 21 is a small health care company based in New York with only 45 employees and an annual revenue of $5.5M.
They specifically list Tencel in that patent announcement
We didn’t receive news that it even passed the toxicity tests.
Now, no news on human trials.
What fell thru??
Hayward needs to be called on the carpet re: Takis pharmaceuticals.
This was supposed to be in human trials in the fall of 2020.
What is the status? Where are the promised updates?
Tali’s pharma/COVID-19 vaccine.
Just disappeared I suppose? Last news was about some animal testing.
They stated toxicity test was done in June. Then nothing.
Hayward did say the APDN test kit was the best and fastest of any existing method. And yes he did say it was 100x faster than existing methods.
And Yes, he did say the company was in negotiations for the sale of such kits
This was over 6 weeks ago. No orders and to rub salt in the wound he posts the Fdaytest results.
Because , being 20th is not good news.
Hayward traditionally only releases hype.
Being 20th on the sensitivity tests is like being close in horseshoes.
It doesn’t seem like something Hayward would want to post on the company website.
My question is why would he?
So, the toxicity tests were completed.
The article says application has been made to the usda for large animal testing.
Well, we’re 2 weeks past the last 2 week delay on the Covid kits. Still no news.
Right , with Hayward it’s the same broken record for over 20 years.
Actually there are two things in that PR quite different from prior information:
1) the APDN Covid 19 test kit is no longer 100X faster than existing tests. It is “One of the fastest....”, meaning other existing tests are just as fast.
2) there is no longer talk of selling the system to major labs or having them adopt the APDN test system. Instead, Hayward is trying to get his own lab authorized for testing.
According to the last transcript, contracts were to be announced in less than two weeks. Instead we get a PR unrelated to prior information on the APDN test kit.
My guess based on past history is that Hayward has sold 5-6 million shares at around $5 bucks??
Every time in the past has been because of massive dilution at the expense of shareholders.
I’ve been saying this for years. And it keeps happening over and over.
Also, in the transcript of third quarter conference call, Hayward says specifically that contracts for Covid test kits would definitely be announced in Less Than two weeks.
It’s been 3 weeks. dead silence
Meanwhile, Takis has dropped off everyone’s radar.
APDN shipped all the dna needed for the toxicity testing 2 months ago . It takes less than 2 weeks for this test. In 10 weeks we have not been given those results.
As far as the Covid19 test kits, major orders were to be announced in less than 2 weeks. It’s been 3 weeks now with no news.
Very, very interesting.
We did not get notice of testing kit contracts in less than two weeks as promised by Hayward in the 3rd Q conference call transcript.
It looks like a press release is coming out tomorrow for Takis Pharmaceuticals.
https://pharmashots.com/press-releases/applied-dna-and-takis-biotech-announce-the-production-of-neutralizing-antibodies-against-sars-cov-2-after-dna-vaccination-in-animals/
Traditionally, the sales are 500-900,000 with a 2 to 3 million loss per quarter.
I haven’t seen any information that would change this pattern.
Perhaps the 4th quarter with Covid kits might change that.
The PR says 10 times faster. So 5,000 tests per day per kit.
The thruput was 500 per day. Anyone know what the enhanced volume is?
APDN supplies dna to a subsidiary of Fuji.
Haven’t heard any recent news on this.
I believe Everledger and APDN have signed agreements.
So, yes, that article directly involves APDN.
I’d like to know the amount of orders for the Covid19 test kits.
These sound far superior with the high throughput and accurate testing.
What I don’t understand within the press release is the multiple vaccines. There would have to one that is most effective with low side effects.
Also , why isn’t Takis vaccine being tested on volunteers now? I thought hyper speed was being applied to the over 140 candidates the FDA is tracking.
If I’m calculating right, the shares have traded 4 times the retail outstanding shares?
18 million shares. How is this possible??
My best guess is that several of the LineaRx/Takis/Evvivax cancer and tumor vaccines are being approved for treatment in the USA and EU. The patent is jointly with them.
Coronavirus Vaccine Tracker
By Jonathan Corum, Denise Grady, Sui-Lee Wee and Carl ZimmerUpdated July 13, 2020
Share on FacebookPost on TwitterMail
Researchers around the world are developing more than 155 vaccines against the coronavirus, and 23 vaccines are in human trials. Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective vaccine by next year.
Work began in January with the deciphering of the SARS-CoV-2 genome. The first vaccine safety trials in humans started in March, but the road ahead remains uncertain. Some trials will fail, and others may end without a clear result. But a few may succeed in stimulating the immune system to produce effective antibodies against the virus.
Here is the status of all the vaccines that have reached trials in humans, along with a selection of promising vaccines still being tested in cells or animals.
New additions and recent updates:
• Australia’s University of Queensland moves to Phase I trials.
• The Chinese company Anhui Zhifei Longcom began Phase II trials.
• Maryland-based Novavax announced U.S. government funding.
• Canada-based Medicago announced a Phase I trial.
• A vaccine by CanSino Biologics was approved for military use.
The Vaccine Testing Process
The development cycle of a vaccine, from lab to clinic.
PRECLINICAL TESTING: Scientists give the vaccine to animals such as mice or monkeys to see if it produces an immune response.
PHASE I SAFETY TRIALS: Scientists give the vaccine to a small number of people to test safety and dosage as well as to confirm that it stimulates the immune system.
PHASE II EXPANDED TRIALS: Scientists give the vaccine to hundreds of people split into groups, such as children and the elderly, to see if the vaccine acts differently in them. These trials further test the vaccine’s safety and ability to stimulate the immune system.
PHASE III EFFICACY TRIALS: Scientists give the vaccine to thousands of people and wait to see how many become infected, compared with volunteers who received a placebo. These trials can determine if the vaccine protects against the coronavirus.
APPROVAL: Regulators in each country review the trial results and decide whether to approve the vaccine or not. During a pandemic, a vaccine may receive emergency use authorization before getting formal approval.
WARP SPEED: The U.S. government’s Operation Warp Speed program is expected to name five or more vaccine projects to receive billions of dollars in federal funding before there’s proof that the vaccines work. We will update the tracker and label the Warp Speed projects when there is an official announcement.
COMBINED PHASES: Another way to accelerate vaccine development is to combine phases. Some coronavirus vaccines are now in Phase I/II trials, for example, in which they are tested for the first time on hundreds of people. (Note that our tracker would count a combined Phase I/II trial as both Phase I and Phase II.)
Genetic Vaccines
Vaccines that use one or more of the coronavirus’s own genes to provoke an immune response.
PHASE II
Moderna’s vaccine dazzled the stock market in May with Phase I data on just eight people, only to see its stock price drop when experts had a lukewarm reaction to the results. The vaccine uses messenger RNA (mRNA for short) to produce viral proteins. The American company is eyeing Phase III trials in July and hopes to have vaccine doses ready by early 2021.
PHASE I PHASE II
The German company BioNTech has entered into collaborations with Pfizer, based in New York, and the Chinese drug maker Fosun Pharma to develop their mRNA vaccine. On July 1, they announced that all the volunteers for their Phase I/II trial produced antibodies against SARS-CoV-2, while some experienced moderate side effects such as sleep disturbances and sore arms. The company expects to start Phase III trials in July. Based on the results so far, the F.D.A. gave the vaccine fast track status on July 13, which speeds up the approval process. If approved, Pfizer said they expect to manufacture up to 100 million doses of the vaccine by the end of this year, and potentially more than 1.2 billion doses by the end of 2021.
PHASE I PHASE II
Imperial College London researchers have developed a “self-amplifying” RNA vaccine, which boosts production of a viral protein to stimulate the immune system. They began Phase I/II trials on June 15 and have partnered with Morningside Ventures to manufacture and distribute the vaccine through a new company called VacEquity Global Health. The researchers expect to know if the vaccine is effective by the end of the year.
PHASE I PHASE II
Indian vaccine-maker Zydus Cadila has created a DNA-based vaccine. On July 3 they announced approval to start human trials, becoming the second company in India to enter the Covid-19 vaccine race after Bharat Biotech.
PHASE I PHASE II
On June 30, the Japanese biotechnology company AnGes announced they had started safety trials on a DNA-based vaccine, developed in partnership with Osaka University and Takara Bio.
PHASE I
On June 30, the American company Inovio announced they had interim Phase I data on their DNA-based vaccine. They found no serious adverse effects, and measured an immune response in 34 out of 36 volunteers. They plan to start Phase II/III trials this summer.
PHASE I
In March, the Trump administration unsuccessfully tried to entice CureVac to move its research from Germany to the United States. In June, the company launched Phase I trials of its mRNA vaccine. The company said its German facility can make hundreds of millions of vaccine doses a year.
PHASE I
The Korean company Genexine started testing the safety of a DNA-based vaccine in June. They anticipate moving to Phase II trials in the fall.
PHASE I
In June, Chinese researchers at the Academy of Military Medical Sciences, Suzhou Abogen Biosciences and Walvax Biotechnology announced they would start their country’s first safety trials on a mRNA-based vaccine, called ARCoV. Earlier studies on monkeys reportedly showed protective effects.
PRECLINICAL
The French pharmaceutical company Sanofi is developing an mRNA vaccine in partnership with Translate Bio. On June 23, they announced they were planning Phase I trials in the fall.
Viral Vector Vaccines
Vaccines that use a virus to deliver coronavirus genes into cells and provoke an immune response.
PHASE II PHASE III
A vaccine in development by the British-Swedish company AstraZeneca and the University of Oxford is based on a chimpanzee adenovirus called ChAdOx1. The vaccine is in a Phase II/III trial in England and Phase III trials in Brazil and South Africa. The project may deliver emergency vaccines by October. In June, AstraZeneca said their total manufacturing capacity stands at two billion doses.
PHASE II LIMITED APPROVAL
The Chinese company CanSino Biologics developed a vaccine based on an adenovirus called Ad5, in partnership with the Institute of Biology at the country’s Academy of Military Medical Sciences. In May, they published promising results from a Phase I safety trial. Unpublished data from Phase II trials demonstrated the vaccine produced a strong immune response, leading the Chinese military to approve it on June 25 for a year as a “specially needed drug.” CanSino would not say whether vaccination would be mandatory or optional for soldiers.
PHASE I
The Gamaleya Research Institute, part of Russia’s Ministry of Health, launched a Phase I trial in June of a vaccine they call Gam-Covid-Vac Lyo. It is a combination of two adenoviruses, Ad5 and Ad26, both engineered with a coronavirus gene.
PRECLINICAL
Researchers at Beth Israel Deaconess Medical Center in Boston are testing an adenovirus called Ad26 in monkeys. Johnson & Johnson announced in June that they would start Phase I/II trials in late July.
PRECLINICAL
The Swiss company Novartis will manufacture a vaccine based on a gene therapy treatment developed by the Massachusetts Eye and Ear Hospital. A virus called an adeno-associated virus delivers coronavirus gene fragments into cells. Phase I trials are set to begin in late 2020.
PRECLINICAL
The American company Merck announced in May it would develop a vaccine from vesicular stomatitis viruses, the same approach it successfully used to produce the only approved vaccine for Ebola. The company is partnering with IAVI.
PRECLINICAL
Merck is also working with Themis Bioscience, an Austrian firm it is acquiring, to develop a second vaccine, which will use the measles virus to carry genetic material into patients’ cells.
PRECLINICAL
Vaxart’s vaccine is an oral tablet containing an adenovirus that delivers coronavirus genes. They are preparing for Phase I trials this summer.
Protein-Based Vaccines
Vaccines that use a coronavirus protein or a protein fragment to provoke an immune response.
PHASE II
In July, the Chinese company Anhui Zhifei Longcom began Phase II trials for a vaccine that is a combination of viral proteins and an adjuvant that stimulates the immune system. The company is part of Chongqing Zhifei Biological Products and has partnered with the Chinese Academy of Medical Sciences.
PHASE I PHASE II
Maryland-based Novavax has developed a way to stick proteins onto microscopic particles. They’ve created vaccines for a number of different diseases using this platform, and their flu vaccine finished Phase III trials in March. The company launched trials for a Covid-19 vaccine in May, and the Coalition for Epidemic Preparedness Innovations has invested $384 million in the vaccine. On July 6, Novavax announced a U.S. government award of $1.6 billion to support clinical trials and manufacturing. If the trials succeed, Novavax expects to deliver 100 million doses for use in the United States by the first quarter of 2021. Plants in Europe and Asia would be able to satisfy more of the world’s demand.
PHASE I
Clover Biopharmaceuticals has developed a vaccine containing a protein from coronaviruses. To further stimulate the immune system, the vaccine is being given in conjunction with so-called adjuvants made by British drugmaker GSK and the American company Dynavax. Investments from CEPI will support the development of manufacturing that could lead to the production of hundreds of millions of doses a year.
PHASE I
The Australian company Vaxine launched a Phase I trial in July. Their vaccine combines viral proteins with an adjuvant that stimulates immune cells.
PHASE I
Canada-based Medicago uses plants to make vaccines. They inject genes into leaves, causing the plant cells to create protein shells that mimic viruses. In July, Medicago announced they would begin Phase I trials on a plant-based Covid-19 vaccine in combination with adjuvants from drug makers GSK and Dynavax.
PHASE I
A vaccine from Australia’s University of Queensland delivers viral proteins altered to draw a stronger immune response. The university and the company CSL launched Phase I trials in July, combining the proteins with an adjuvant made by GSK. If the results are positive, CSL expects to make tens of millions of doses.
PRECLINICAL
After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers are reviving the project in partnership with the Texas Children’s Hospital.
PRECLINICAL
A vaccine in development by the University of Pittsburgh, called PittCoVacc, is a skin patch tipped with 400 tiny needles made of sugar. When placed on the skin, the needles dissolve and deliver virus proteins into the body.
PRECLINICAL
In addition to their mRNA vaccine, Sanofi is developing a vaccine based on viral proteins. They are producing the proteins with engineered viruses that grow inside insect cells. GSK will supplement these proteins with adjuvants that stimulate the immune system. Sanofi has said it could produce at least 600 million doses a year if the vaccine succeeds in trials.
Whole-Virus Vaccines
Vaccines that use a weakened or inactivated version of the coronavirus to provoke an immune response.
PHASE III
After promising early testing, the state-owned Chinese company Sinopharm announced in June that it would be moving into Phase III trials. They reached an agreement with the United Arab Emirates to start testing the efficacy of an inactivated virus vaccine in the Gulf state.
PHASE III
The private Chinese company Sinovac Biotech is testing an inactivated vaccine called CoronaVac. In June the company announced that Phase I/II trials on 743 volunteers found no severe adverse effects and produced an immune response. Sinovac then launched a Phase III trial in Brazil in July. The company is also building a facility to manufacture up to 100 million doses annually.
PHASE II
Researchers at the Institute of Medical Biology at the Chinese Academy of Medical Sciences, which has invented vaccines for polio and hepatitis A, started a Phase II trial of an inactivated virus vaccine in June.
PHASE I PHASE II
In collaboration with the Indian Council of Medical Research and the National Institute of Virology, the Indian company Bharat Biotech designed a vaccine called Covaxin. It is an inactivated rabies virus engineered to carry proteins from the coronavirus. Phase I/II trials are scheduled to begin this month. The Indian Council of Medical Research reportedly envisions having the vaccine ready for public use on August 15, but this target has been met with skepticism.
Repurposed Vaccines
Vaccines already in use for other diseases that may also protect against Covid-19.
PHASE III
The Bacillus Calmette-Guerin vaccine was developed in the early 1900s as a protection against tuberculosis. The Murdoch Children’s Research Institute in Australia is conducting a Phase III trial, and several other trials are underway to see if the vaccine partly protects against the coronavirus.
Note: Vaccines will be added to the tracker when they reach Phase I, and tracked until they succeed or fail.
Did we miss something? To notify The Times of new developments, send updates to vaccinetracker@nytimes.com.
Tracking the Coronavirus
World maps | U.S. city dashboard | State reopenings
Additional reporting by Carlos Tejada and Li Cao.
Sources: World Health Organization, National Institute of Allergy and Infectious Diseases, National Center for Biotechnology Information, New England Journal of Medicine
Site Information Navigation
© 2020 The New York Times Company
Contact UsWork with usAdvertiseYour Ad ChoicesPrivacyTerms of ServiceTerms of SaleSite MapHelpSubscriptions
Do Not Sell My Personal Information
Subscribe to the New York Times.
Where’s the mention of APDN.
According to Hayward, APDN and Takis have a joint development agreement.
It seems that any subsequent agreements Takis makes would require APDN to also sign on.
OR is APDN simply supplying DNA to Takis like it does for multiple research facilities?
If true, then the Takis press releases were not true and there was not joint development agreement.
It was shortly after the Takis PRs that Maxim started calling me to buy more stock directly from the company.
Don’t have an agenda. Just want press releases when new business is initiated. Conversely, I want press releases when it falls through.
Hayward is quick to announce new agreements and has also promised updates that never happened.
Shareholders had to call the other entities involved to find out the deals fell through.
Theracan, Organic cotton and fertilizers come immediately to mind. There are many more going back years.
In all these cases Sanjay was confronted via email and phone calls. But to no avail.
I’m just saying. Takis smells the same.